Xentria Readies First Trial of XTMAB-16 for Sarcoidosis

Xentria Readies First Trial of XTMAB-16 for Sarcoidosis

297829

Xentria Readies First Trial of XTMAB-16 for Sarcoidosis

The U.S. Food and Drug Administration (FDA) has approved beginning clinical trials testing XTMAB-16, Xentria’s investigational TNF-alpha inhibitor for the treatment of sarcoidosis. The first, a Phase 1 trial evaluating the therapy in healthy volunteers, is expected to start in July at the Parexel Baltimore Early Phase Clinical Unit, Medstar Harbor Hospital, Baltimore, Maryland. “We believe XTMAB-16 has the potential to offer significant benefits to patients with sarcoidosis,” Thomas Shea, Xentria’s president, said in a…

You must be logged in to read/download the full post.